Teresa Branco
Director of TO BE.
The recent decision by the Food and Drug Administration (FDA)in the United States to remove the safety warning associated with the use of estrogen alone represents a significant shift in how hormone therapy is viewed in postmenopausal women. Furthermore, this update follows an in-depth reassessment of the available scientific evidence and changes how the risk-benefit profile of this treatment should be interpreted.
According to Medscape Portugal magazine , the FDA has withdrawn the estrogen warning that linked the use of estrogen alone to an increased risk of dementia in postmenopausal women. The agency thus acknowledges that current scientific data do not consistently support this link when the therapy is properly prescribed and monitored.
What the previous alert was about
For several years, estrogen-based medications administered alone—that is, without progesterone—carried a safety warning regarding a potential increased risk of dementia in women over the age of 65.
At the time, this warning stemmed from initial interpretations of subgroup analyses from the Women’s Health Initiative (WHI) study, which has been widely cited in the scientific literature. However, over time, the medical community began to question the generalizability of these findings.
This is because the data did not adequately distinguish between important factors such as:
- Age at which hormone therapy is initiated;
- Type of estrogen used;
- Dose administered;
- Duration of treatment;
- The woman's individual clinical context.
For this reason, it has become clear that these results need to be reevaluated.
Why did the FDA change its position?
According to Medscape, the FDA’s decision is based on a more up-to-date and rigorous analysis of the available scientific evidence. Consequently, it was concluded that there is no clear causal association between the use of estrogen alone and an increased risk of dementia when the therapy is administered appropriately.
Furthermore, the FDA itself acknowledges that the previous warning could have led to overly alarmist interpretations. As a result, many women ended up avoiding a treatment that could have improved their quality of life.
Therefore, when the FDA lifts the warning regarding estrogen, it paves the way for a more balanced approach based on current scientific evidence.
The impact of this decision on clinical practice
Despite this change, it is important to note that hormone therapy is not without risks and should not be used indiscriminately. On the contrary, an individualized assessment remains essential.
Therefore, the treatment decision should take into account:
- Medical history;
- Symptoms experienced;
- Woman's age;
- Time since menopause;
- Therapeutic goals;
- Presence of risk factors.
Nevertheless, the FDA’s decision to lift the estrogen warning helps clarify the scientific basis for this treatment and reduces the stigma created by broad-based warnings.
In addition, this update provides an opportunity for healthcare professionals to strengthen communication with patients, thereby promoting more informed and conscious decisions.
What changes for women
For many women, especially those who have had a hysterectomy and for whom estrogen therapy alone is a common treatment option, this decision can provide greater peace of mind.
Currently, hormone therapy remains one of the most effective approaches for relieving symptoms associated with menopause, including:
- Confrontations;
- Sleep disturbances;
- Mood swings;
- Tiredness;
- Impact on quality of life.
In this regard, the FDA’s decision to lift the warning regarding estrogen allows the decision to initiate or continue this type of therapy to be made with greater confidence and a stronger scientific basis.
An approach more in line with personalized medicine
The position now taken by the FDA reflects a more modern approach to medicine, focused on personalized care. After all, menopause is not a uniform condition, and every woman responds differently to hormone therapy.
Therefore, rather than universal rules, the importance of the following is emphasized:
- Close clinical monitoring;
- Regular reassessments;
- Transparent communication;
- A relationship of trust between healthcare professionals and patients.
When appropriately prescribed, hormone therapy can be an important tool in promoting well-being and health in the medium and long term.
Up-to-date information and more informed decisions
The FDA’s decision is not merely a technical change to drug labels. In practice, it also underscores the importance of updating medical recommendations in light of scientific advances.
Furthermore, it contributes to a more balanced discourse on women’s health, moving away from overly conservative approaches and promoting a more contextualized view of menopause and hormone therapy.
Today, as the FDA lifts its warning regarding estrogen, the need for individualized clinical decisions—informed by and supported by the latest scientific evidence—is further underscored.
How TO BE. can help you
In a landscape where scientific knowledge continues to evolve, it becomes even more important to have access tomultidisciplinary, personalized, and patient-centered medical care.
In TO BE., women’s health care is provided through an integrated approach based on active listening, up-to-date scientific knowledge, and personalized care.
Rather than offering generic answers, the clinic aims to help each woman:
- Understand your body;
- Recognizing hormonal changes;
- Learn about the available treatment options;
- Make informed and confident decisions.
At a time when the FDA is lifting its warning about estrogen and the topic is gaining a new scientific perspective, TO BE. positions itself as a source of support, trust, and guidance.
Schedule your consultation and take the first step toward understanding your body based on science, safety, and specialized care.
